Results 21 to 30 of about 2,670,563 (294)

Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR

npj Breast Cancer, 2022
We investigated the patterns of recurrence and primary endocrine resistance according to estrogen receptor (ER) alpha gene (ESR1) mutations, as assessed by digital droplet (dd) PCR, in patients with non-metastatic ER+ breast cancer.
Sung Gwe Ahn, Soong June Bae, Yoonjung Kim, Jung Hwan Ji, Chihhao Chu, Dooreh Kim, Janghee Lee, Yoon Jin Cha, Kyung-A Lee, Joon Jeong   +9 more
doaj   +1 more source

Comprehensive Transcriptomic Analysis Reveals Dysregulated Competing Endogenous RNA Network in Endocrine Resistant Breast Cancer Cells

Frontiers in Oncology, 2020
BackgroundTamoxifen and fulvestrant, both approved for endocrine therapy, have remarkably increased the prognosis of hormone receptor-positive breast cancer patients. However, acquired resistance to endocrine therapy greatly reduces its clinical efficacy.
Liang Gao, Kunwei Shen, Ni Yin, Min Jiang   +3 more
doaj   +1 more source

Action of Estrogen In Breast Cancer: A review Study

Kufa Journal for Nursing Sciences, 2022
Estrogen hormone is one of the steroid hormones has a critical role in breast cancer etiology. It has been implicated in proliferation and differentiation of cells through its action promoting binding of its receptor to DNA, changing transcriptional ...
Suad Ibrahim, Rachel Berkson
doaj   +1 more source

Dysregulation of TLR2 Serves as a Prognostic Biomarker in Breast Cancer and Predicts Resistance to Endocrine Therapy in the Luminal B Subtype

Frontiers in Oncology, 2020
Background: Breast cancer (BCa) is a serious global health burden among females, and the development of resistance represents an important challenge to BCa treatment. Here, we examined the expression of toll-like receptor 2 (TLR2) in BCa patients and the
Yunmei Wang, Yunmei Wang, Shuguang Liu, Yanjun Zhang, Jin Yang   +4 more
doaj   +1 more source

Sodium/glucose cotransporter 1-dependent metabolic alterations induce tamoxifen resistance in breast cancer by promoting macrophage M2 polarization

Cell Death and Disease, 2021
Endocrine therapy is the standard treatment for estrogen receptor (ER)-positive breast cancer, but tumors eventually develop resistance. However, endocrine therapy resistance mechanisms mediated through interactions between breast cancer cells and tumor ...
Xingjian Niu, Jianli Ma, Jingtong Li, Yucui Gu, Lei Yin, Yiran Wang, Xiaoping Zhou, Jinlu Wang, Hongfei Ji, Qingyuan Zhang   +9 more
doaj   +1 more source

A hard pill to swallow: a qualitative study of women’s experiences of adjuvant endocrine therapy for breast cancer [PDF]

, 2014
Objective: To explore women’s experiences of taking adjuvant endocrine therapy as a treatment for breast cancer and how their beliefs about the purpose of the medication, side effects experienced and interactions with health professionals might influence
McCowan, Colin, Harrow, Alison, Thompson, Alastair M., McCowan, C, Radley, Andrew, Wells, Mary, Radley, Andrew; id_orcid, Parsons, Mark, Dryden, R, Dryden, Ruth, Thompson, Alastair M, Parsons, M, Wells, M, Thompson, Alastair, Radley, A, Thompson, AM, Harrow, A   +16 more
core   +1 more source

FDXR drives primary and endocrine-resistant tumor cell growth in ER+ breast cancer via CPT1A-mediated fatty acid oxidation

Frontiers in Oncology, 2023
BackgroundThe majority of breast cancers (BCs) expressing estrogen receptor (ER) have shown endocrine resistance. Our previous study demonstrated that ferredoxin reductase (FDXR) promoted mitochondrial function and ER+ breast tumorigenesis.
Chaojun Yan, Ronghui Gao, Chuan Gao, Kai Hong, Meng Cheng, Xiaojing Liu, Qing Zhang, Qing Zhang, Jing Zhang   +8 more
doaj   +1 more source

Identification and mechanisms of endocrine resistance [PDF]

Breast Cancer Research, 2008
Resistance is the major factor limiting endocrine therapy. This short communication defines the different types of resistance, the mechanisms by which resistance may occur and how they may be identified.
openaire   +2 more sources

Endocrine therapy resistance: what we know and future directions

Exploration of Targeted Anti-tumor Therapy, 2022
Endocrine resistance is a major hurdle in the treatment of estrogen receptor (ER)-positive breast cancer. When abnormally regulated, molecular signals responsible for cellular proliferation, as well as ER itself, allow for cellular evasion of ER ...
David Musheyev, Anya Alayev
doaj   +1 more source

Increased STAT1 signaling in endocrine-resistant breast cancer [PDF]

, 2014
Funding: China Scholarship Council, University of Edinburgh, Scottish Funding Council and Breakthrough Breast Cancer.Proteomic profiling of the estrogen/tamoxifen-sensitive MCF-7 cell line and its partially sensitive (MCF-7/LCC1) and fully resistant (MCF-
Thomas Jeremy S., Faratian Dana, Huang Rui, Sims Andrew H., Dana Faratian (171110), Simon P. Langdon, Danielle Wilson (550968), David J. Harrison (171106), Jeremy S. Thomas, Dana Faratian, Rui Huang, Wilson Danielle, Harrison David J., David J. Harrison, Danielle Wilson, Simon P Langdon, Thomas, Jeremy S, Sims, Andrew H, Andrew H. Sims (108040), Harrison, David J, Rui Huang (141490), Huang, Rui, Simon P. Langdon (207293), Wilson, Danielle, David J Harrison, Thomas, Jeremy, Langdon Simon P., Faratian, Dana, Andrew H. Sims, Andrew H Sims, Jeremy S Thomas, Jeremy S. Thomas (550969), Langdon, Simon P   +32 more
core   +2 more sources